After analysis of the existing data, it was determined that additional skin biopsy samples would not be required to determine study outcome.

This study will look at the skin accumulation of vildagliptin and its two major metabolites, LAY151 and LAF237-O-Glucuronide, after vildagliptin 50 mg given orally twice a day for 10 days in both healthy volunteers and patients with type 2 diabetes.

Inclusion Criteria:

• Healthy volunteers and patients with type 2 diabetes
• Non-smoking, Caucasian and African American, male and female (postmenopausal, surgically sterile or using double-barrier method of contraception) subjects between 30 and 65 years of age (inclusive)
• Type 2 diabetics on metformin and/or sufonylurea

Exclusion Criteria:

• History of type 1 diabetes or insulin use
• History of coagulation abnormalities
• History of abnormal heart conditions
• Pregnancy or breastfeeding

Other protocol-defined inclusion/exclusion criteria may apply